Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.
- NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_assertion description "[The genetic polymorphism affecting TPMT activity displays an important inter-subject variability in metabolites pharmacokinetics and influences the balance between 6-MP efficacy and toxicity: patients with high 6-TGN levels are at risk of myelosuppression while patients with high levels of methylated derivates are at hepatotoxic risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.
- NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_assertion evidence source_evidence_literature NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.
- NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_assertion SIO_000772 22421815 NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.
- NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_assertion wasDerivedFrom befree-20140225 NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.
- NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_assertion wasGeneratedBy ECO_0000203 NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.
- befree-20140225 importedOn "2014-02-25" NP406669.RA06J1FQnSKjKtN3DYvKHgwId8e9vouEl0P2PFh_sRC_A130_provenance.